Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$30.07 USD
+0.76 (2.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $30.25 +0.18 (0.60%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
SUPN 30.07 +0.76(2.59%)
Will SUPN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SUPN
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
Other News for SUPN
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Notable Two Hundred Day Moving Average Cross - SUPN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
Supernus Provides Regulatory Update for SPN-830
Supernus stock slides as FDA rejects Parkinson's disease infusion device